Replies to post #25252 on Biotech Values

[DewDiligence]

GTCB ReadMeFirst

[Updated share count; deleted obsolete entries.]


What is GTC’s business all about?
#msg-9243634 Jan 2006 interview with CEO, Geoff Cox
#msg-9352093 2002 interview with Tom Newberry (dated, but informative)


Valuation and finances
#msg-10169296 Updated share count (from 10K filing)
#msg-10018565 4Q05 financial report
#msg-10018657 Notes on the 4Q05 report
#msg-8794102 Most recent financing
#msg-9892845 Buyout musings


ATryn development program in Europe
#msg-9840217 EMEA rejects application (2/23/06)
#msg-9856708 Transcript from 2/23/06 CC
#msg-9855935 Who’s to blame?
#msg-8316050 LEO partnership announcement
#msg-8496664 Notes re LEO from 3Q05 CC


ATryn development program in U.S.
#msg-9268492 U.S. ATryn timeline
#msg-6543884 Non-availability of competing antithrombin
#msg-5607789 Efficacy endpoint is *clinical* DVT
#msg-5609005 Design of control arm
#msg-6632420 Patient eligibility and exclusions


ATryn vs plasma-derived antithrombin
#msg-4372780 Risks of plasma-derived proteins
#msg-7306242 Which one will doctors prescribe?
#msg-7221666 Price, availability of commercial plasma-derived AT
#msg-7327529 Heparin contamination?


Miscellaneous info on ATryn and antithrombin
#msg-9502819 A patient’s story
#msg-9819574 ATryn vs oral anticoagulants
#msg-7268415 ATryn in sepsis (please follow reply chain)
#msg-4316445 Bioterror contract with U.S. army
#msg-7050226 Abstract on antithrombin deficiency in pregnancy


Non-ATryn development programs
Background info: http://www.transgenics.com/products/prod.html
#msg-5054169 Human serum albumin
#msg-6488263 Alpha-1 Antitrypsin market size
#msg-7293132 Alpha-1 Antitrypsin market size (more)
#msg-8163705 Merrimack program in RA
#msg-8111599 Musings on economics of Merrimack collaboration
#msg-8111467 Merrimack program in psoriasis
#msg-7136629 Collaboration with Scancell
#msg-8388346 Notes from 10Q filing


Intellectual property
#msg-9174865 Production (“milk”) patent
#msg-7179529 Purification patent
#msg-5027284 Nuclear-transfer IP (Geron)
#msg-4107224 IP license to Nexia


Musings on competition and business model
#msg-4364077 (Urche)
#msg-4359874 (Dew)
#msg-6242807 (Poorgradstudent)
#msg-2820748 (Biowatch)
#msg-8863527 Companies to watch (Drug Discovery & Development)
#msg-6240481 Companies to watch (Frost & Sullivan)
#msg-7542154 Origen’s transgenic chickens


Miscellaneous topics
#msg-4787482 High-pedigreed GTC directors


Feature stories on GTCB and transgenics
#msg-9872282 Nature.com (2/24/06)
#msg-9860806 Boston Globe (2/24/06)
#msg-9834674 BBC (2/20/06 video)
#msg-9243634 Red Herring (1/06)
#msg-9143261 Business Week (1/06)
#msg-8162424 Scientific American (11/05)
#msg-6806806 Wall St Transcript interview with Tom Newberry (6/05)
#msg-6775592 Newsweek special issue on healthcare (6/05)
#msg-6276428 Worcester, MA Telegram & Gazette (5/05)
#msg-7431316 Nature Biotechnology (10/04)
#msg-4057315 The Economist (9/04)
#msg-3990950 Chemical Market Reporter (9/04)
#msg-3631094 Boston Herald on bioterror (7/04)


iHub reader survey
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=1418 (survey #46)